431 completed, 172 recruiting, 127 unknown, 70 terminated. 274 Phase 2, 231 Not applicable, 171 Phase 1, 90 Phase 3, 20 Early Phase 1.
Follow this condition Literature Review of Amyotrophic Lateral Sclerosis trials Research Report on Amyotrophic Lateral Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2028-09-01 | 2026-09-11 |
| Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS) B cell infusion - ALS - Amyotrophic Lateral Sclerosis | Phase 1 | Not yet recruiting | Mark Poznansky | 10 | 2027-09-01 | 2026-09-24 |
| Safety Study of XT-150 in Participants With ALS XT-150 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Xalud Therapeutics, Inc. | 8 | 2027-03-01 | 2026-07-29 |
| Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS) | Not applicable | Recruiting | Johns Hopkins University | 5 | 2027-01-01 | 2026-10-09 |
| Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) Q-Cells - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Q Therapeutics, Inc. | 30 | 2026-12-01 | 2026-07-08 |
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| Brain-Computer Interface Communication Device for People With ALS Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device - Amyotrophic Lateral Sclerosis | Not applicable | Recruiting | Cognixion | 30 | 2026-11-15 | 2026-10-16 |
| A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS). LY3873862, CYP450 Drug Cocktail, Placebo - Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System | Phase 1 | Not yet recruiting | Eli Lilly and Company | 32 | 2026-11-01 | 2026-10-20 |
| Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS) Chronic speech BCI - Locked in Syndrome, ALS (Amyotrophic Lateral Sclerosis) | Not applicable | Not yet recruiting | University Hospital, Grenoble | 3 | 2026-10-10 | 2026-07-13 |
| A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) BIIB147, Placebo - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Biogen | 69 | 2026-10-07 | 2026-10-19 |
| iBCI Optimization for Veterans With Paralysis Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis | Not applicable | Not yet recruiting | VA Office of Research and Development | 2 | 2026-10-02 | 2026-07-27 |
| Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS β-hydroxy-β-methylbutyrate (HMB) - Amyotrophic Lateral Sclerosis ALS | Phase 1 | Not yet recruiting | Duke University | 100 | 2026-10-01 | 2026-09-08 |
| Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis IBM, Inclusion Body Myositis | Recruiting | Johns Hopkins University | 30 | 2026-10-01 | 2026-09-16 | |
| Development in Home Mechanical Ventilation for Patient With Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, Home Mechanical Ventilation | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 400 | 2026-10-01 | 2026-09-15 | |
| Colchicine Effect on Amyotrophic Lateral Sclerosis Patients Colchicine 0.5 MG Oral Tablet, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria di Modena | 87 | 2026-10-01 | 2026-09-10 |
| Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) Orelabrutinib - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 | Not yet recruiting | Liu Qing | 12 | 2026-10-01 | 2026-10-15 |
| Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis Cyclophosphamide, Riluzole - Amyotrophic Lateral Sclerosis | Phase 2 | Not yet recruiting | Huashan Hospital | 60 | 2026-10-01 | 2026-09-22 |
| Efficacy and Safety of Tazbentetol in ALS Participants Tazbentetol, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 430 | 2026-10-01 | 2026-09-10 |
| Metabolism and Nutrition in MND Amyotrophic Lateral Sclerosis (ALS), Motor Neurone Disease (MND) | Not yet recruiting | Guy's and St Thomas' NHS Foundation Trust | 12 | 2026-10-01 | 2026-10-01 | |
| Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis RNS60, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | Revalesio Corporation | 2026-10-01 | 2026-04-16 |
Showing 20 of 972. Sign in to see all of them.
Motor Neuron Disease (144) · Parkinson Disease (49) · Neurodegenerative Diseases (47) · Neuromuscular Diseases (39) · Spinal Cord Injuries (37) · Alzheimer Disease (34) · Frontotemporal Dementia (30) · Multiple Sclerosis (30) · Muscular Atrophy, Spinal (29) · Nervous System Diseases (26) · Stroke (23) · Quadriplegia (20) · Muscular Dystrophies (19) · Movement Disorders (16)
Metabolic Diseases (972) · Nutritional and Metabolic Diseases (972) · Proteostasis Deficiencies (972) · Spinal Cord Diseases (968) · TDP-43 Proteinopathies (967) · Central Nervous System Diseases (964) · Nervous System Diseases (946) · Neuromuscular Diseases (933) · Neurodegenerative Diseases (925) · Motor Neuron Disease (828) · Pathological Conditions, Signs and Symptoms (146) · Brain Diseases (106) · Signs and Symptoms (100) · Neurologic Manifestations (81) · Pathologic Processes (74)
Riluzole (24) · Blood Specimen Collection (13) · Spinal Puncture (9) · Dexpramipexole (8) · Edaravone (8) · sodium phenylbutyrate and taurursodiol (7) · CK-2017357 (6) · Noninvasive Ventilation (6) · Sodium Chloride (6) · Transcranial Magnetic Stimulation (6) · Creatine (5) · Memantine (5) · arimoclomol (5) · Brain-Computer Interfaces (4) · Copper (4)
Peking University Third Hospital (21) · Assistance Publique - Hôpitaux de Paris (20) · Massachusetts General Hospital (20) · Johns Hopkins University (12) · National Institute of Neurological Disorders and Stroke (NINDS) (11) · University of Michigan (11) · Drexel University College of Medicine (10) · Mayo Clinic (10) · Biogen (9) · Cytokinetics (9) · Knopp Biosciences (9) · Merit E. Cudkowicz, MD (9) · Amylyx Pharmaceuticals Inc. (8) · Duke University (8) · University Hospital, Tours (8)
United States (435) · France (130) · Italy (88) · Canada (81) · Germany (74) · United Kingdom (68) · Netherlands (65) · Belgium (57) · Spain (55) · China (54) · Australia (43) · Sweden (33) · Ireland (32) · Poland (28) · Japan (20)
Merit Cudkowicz, MD (10) · Jeremy Shefner, MD, PhD (8) · Bjorn Oskarsson, MD (6) · Dominic Rowe, MD (5) · Dongsheng Fan (5) · Merit Cudkowicz, MD, MSc (5) · Terry Heiman-Patterson, MD (5) · Benjamin R Brooks, MD (4) · Hamid Gourabi, PhD (4) · Jakub M Antczak, MD (4) · Jane Huggins, PhD (4)
PMID 36008843, PMID 16434671, PMID 17980667, PMID 19251627, PMID 22415951, PMID 22529995, PMID 23300829, PMID 23463272, PMID 23952636, PMID 24067398, PMID 25982504, PMID 26751635, PMID 29287521, PMID 30124008, PMID 30814647, PMID 32896088, PMID 34433481, PMID 34536404, PMID 35532908, PMID 35577511, PMID 35790423, PMID 37254449, PMID 37396808, PMID 38010108, PMID 39457678, PMID 40067754, PMID 40067755, PMID 40067821, PMID 41224659, PMID 41366786, PMID 10540002, PMID 11015796, PMID 11050032, PMID 11586297, PMID 11750036, PMID 14718694, PMID 15084121, PMID 15505150, PMID 15657798, PMID 15790844, PMID 15823706, PMID 15831718, PMID 16267188, PMID 16636275, PMID 16741123, PMID 16822964, PMID 16849828, PMID 16894118, PMID 16900450, PMID 17018025
2023 (10), 2017 (6), 2025 (5), 2019 (3), U54NS092091 (3), 1OT2NS136938 (2), 1OT2NS136939 (2), 2014 (2), 2015 (2), P01AG066597 (2), P01NS084974 (2), R01DC021714 (2), U01NS049640 (2), 1DP2DC021055 (1), 2016 (1)